Business Context and Reporting Period
This Form 8-K filing by Orthodontix, Inc. (not Protalix Biotherapeutics, Inc.) covers the event date of November 30, 2005. The company is a Florida corporation based in Miami, Florida, currently seeking a merger or business combination with an operating company.
Key Financial Metrics
The filing details a specific equity transaction rather than comprehensive financial statements. On November 30, 2005, the Company sold 2,915,428 newly issued shares of common stock to Frost Gamma Investments Trust for a total purchase price of $494,000. There were no underwriting discounts or commissions associated with this sale. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity beyond this transaction.
Material Changes
The primary material change is the acquisition of control by Dr. Phillip Frost. Following this purchase, the Frost Gamma Investments Trust owns 2,965,428 shares, representing 51 percent of Orthodontix, Inc. This transaction was executed under the Section 4(2) exemption of the Securities Act of 1933.
Guidance, Outlook, and Risks
Management commentary indicates that Orthodontix intends to effect a merger or other business combination with an operating company. The filing does not provide specific financial guidance, risk factors, or contingencies beyond the standard disclosure of the unregistered sale of equity securities.
Investor Verification Checklist
- Verify the exact ownership percentage of the Frost Gamma Investments Trust post-transaction (stated as 51%).
- Confirm the total number of shares outstanding to validate the 51% control calculation.
- Review the status of the intended merger or business combination with an operating company.
- Check for subsequent filings regarding the integration of Dr. Phillip Frost's leadership or strategic direction.